The FecalSwab™ system (Copan Italia, Brescia, Italy) is a convenient alternative to bulk stool for the diagnosis of enteric pathogens. Although U.S. Food and Drug Administration (FDA) approved for transport and culture of enteric bacterial pathogens, the FecalSwab™ has not been well assessed for its suitability with molecular platforms. In this study, we evaluated the FecalSwab™ as a specimen type for the BD MAX™ System using the viral and bacterial enteric panels (BD Diagnostics, Baltimore, USA). One-hundred eighty-six unpreserved stool specimens were collected and used to prepare matched bulk stool and FecalSwab™ samples. Performance was equivalent (P >0.48) to bulk stool for all targets when 50 μl of FecalSwab™ specimen was loaded onto the BD MAX™ assays. As stool specimens are often collected off-site from the clinical microbiology laboratory and require transport, we assessed the stability of stool specimens stored for up to 14 days at 40C, 220C, or 350C to account for varying transportation conditions. Molecular detection for the majority of viral targets (excluding astrovirus) was unaffected (ΔCT ≤1) by sample storage temperature over the two-week period; however, detection of enteric bacteria was variable if specimens were not refrigerated (220C or 350C). By demonstrating equivalent performance to matched bulk stool and maintaining molecular detection sensitivity when stored at 4°C, we suggest that the FecalSwab™ is a suitable specimen type for enteropathogen diagnostics on the BD MAX™ System.